TC BioPharm (Holdings) plc American Depositary Receipt Financials
TCBPY
All currency values in £ millions unless otherwise noted
| Income Statement | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 |
|---|---|---|---|---|
| Revenues | ||||
| Revenue | £0 | £0 | £4 | £2 |
| Operating Income | -£13 | -£14 | -£12 | -£7 |
| Non-Operating | ||||
| Net Interest Expense | £0 | -£0 | -£7 | -£3 |
| Income Tax Expense | -£1 | -£1 | -£2 | -£1 |
| Net Income | ||||
| Net Income | -£12 | -£6 | -£1 | -£14 |
| Per Share Data | ||||
| Revenue Per Share | £0.00 | £0.00 | £17,888.06 | – |
| EPS (Basic) | -£6,320.89 | -£3,072.00 | -£6,112.00 | – |
| EPS (Diluted) | -£6,320.89 | -£3,072.00 | -£6,112.00 | – |
| Shares Outstanding | 1,922.836 | 1,922.836 | 214.922 | – |
TC BioPharm (Holdings) plc American Depositary Receipt (TCBPY) financials: revenue, profit and margins
TC BioPharm (Holdings) plc American Depositary Receipt (TCBPY) generated about £0.00 in revenue and -£12 million in net income over the trailing twelve months, growing at roughly 94.3% a year. Figures are from company filings; this is analysis, not investment advice.
Frequently asked
What is TC BioPharm (Holdings) plc American Depositary Receipt's (TCBPY) revenue?+
TC BioPharm (Holdings) plc American Depositary Receipt generated about £0.00 in revenue over the trailing twelve months. Revenue has grown at roughly 94.3% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is TC BioPharm (Holdings) plc American Depositary Receipt profitable?+
TC BioPharm (Holdings) plc American Depositary Receipt reported about -£12 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
How fast is TC BioPharm (Holdings) plc American Depositary Receipt growing?+
TC BioPharm (Holdings) plc American Depositary Receipt's revenue has compounded at roughly 94.3% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside TCBPY's margins and free cash flow. This is analysis from company filings, not investment advice.
Peers
Biotechnology · Pick stocks to compare with TCBPY
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing TCBPY
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.